Skip to main content

Advertisement

Table 2 Comparison of dosimetric results for 3DCRT and VMAT plans

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

  3DCRT VMAT P
PTV
 V95 % (%) 93.6 ± 10.2 [52.5; 100.0] 97.2 ± 21.8 [32.4; 99.8] ns
 V107 % (%) 0.5 ± 0.9 [0; 2.8] 0.1 ± 0.3 [0.0; 1.4] ns
 Vol (cm3) 203.1 ± 101.4 [91.2; 490.8] 274.8 ± 112.9 [99.6; 507.7] ns
 D99 % (%) 85.4 ± 19.7 [4.37; 97.30] 82.8 ± 23.7 [16.8; 97.2] ns
 HI 0.13 ± 0.8 [0.04; 1.21] 0.09 ± 0.04 [0.03; 0.50] 0.04
 CI 1.40 ± 0.30 [1.02; 2.09] 1.04 ± 0.02 [1.00; 1.09] <0.01
Brain-PTV
 V3Gy(%) 75.0 ± 18.1 [42.0; 100.0] 79.9 ± 14.8 [51.9; 99.4] ns
 V5Gy (%) 69.3 ± 18.1 [42.0; 100.0] 72.9 ± 16.3 [46.6; 98.0] ns
 V20Gy (%) 35.4 ± 16.1 [14.2; 75.5] 32.6 ± 13.3 [13.9; 53.7] ns
 V35Gy (%) 21.6 ± 12.6 [3.5; 48.9] 12.1 ± 5.6 [5.1; 24.1] 0.03
 Dmean (Gy) 18.8 ± 7.0 [10.8; 66.4] 16.5 ± 4.8 [9.9; 24.9] ns
 D1 % (Gy) 58.9 ± 5.1 [39.9; 65.3] 55.9 ± 1.8 [53.4; 59.3] ns
Ipsilateral Lens
 D1 % (Gy) 6.4 ± 4.5 [0.5; 14.9] 5.3 ± 2.8 [0.6; 13.9] ns
Controlateral Lens
 D1 % (Gy) 3.6 ± 4.9 [0.4; 19.8] 5.1 ± 4.2 [0.7; 21.1] ns
Ipsilateral Optic Nerve
 D1 % (Gy) 19.6 ± 19.2 [1.0; 57.2] 25.5 ± 18.2 [0.9; 53.7] ns
Controlateral Optic Nerve
 D1 % (Gy) 10.1 ± 11.7 [0.7; 47.2] 12.9 ± 8.9 [1.3; 36.6] ns
Chiasm
 D1 % (Gy) 22.2 ± 18.1 [1.4; 56.7] 32.0 ± 18.6 [1.8; 55.9] 0.02
Brainstem
 D1 % (Gy) 33.5 ± 18.4 [1.7; 57.3] 40.9 ± 18.0 [4.9; 62.5] 0.04